5,5-Diphenyl-glykocyamidin | 26975-70-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5,5-Diphenyl-glykocyamidin
• 英文别名: 5,5-Diphenylglycocyamidin；2-amino-4,4-diphenyl-1H-imidazol-5-one
• CAS: 26975-70-2
• 化学式: C₁₅H₁₃N₃O
• mdl: MFCD09028321
• 分子量: 251.288
• InChiKey: KMAGLUVYQQBXIR-UHFFFAOYSA-N

物化性质

• 熔点：
  >290 °C
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  2,6-二甲苯基异氰酸酯 、 5,5-Diphenyl-glykocyamidin 以 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 生成 1-(2,6-dimethyl-phenyl)-3-(4-oxo-5,5-diphenyl-4,5-dihydro-1H-imidazol-2-yl)-urea
  参考文献：
  名称：

  4-Oxo-2-imidazolidinylidene ureas

  摘要：

  类似4-氧代-2-咪唑啉基脲和4-氧代-2-六氢嘧啶基脲的化合物，可用作抗分泌剂和中枢神经系统（CNS）抑制剂。

  公开号：

  US03983135A1
• 作为产物：
  描述：

  2,2-二苯基甘氨酸 在 palladium on activated charcoal 水 、 ammonium formate 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 7.0h， 生成 5,5-Diphenyl-glykocyamidin
  参考文献：
  名称：

  Synthesis and anticonvulsant activity of 2-iminohydantoins

  摘要：

  Iminohydantoins selectively substituted at position C-5 and their 1-carbobenzoxy derivatives have been synthesized, and their anticonvulsant activity was evaluated in mice. In general the more lipophilic 1-carbobenzoxy iminohydantoins were more potent than the unsubstituted counterparts. Evaluation of the individual enantiomers of the chiral iminohydantoins showed that the anticonvulsant activity resided primarily in the S isomers. In this study, (S)-(+)-1-carbobenzoxy-5-isobutyl-2-iminohydantoin (9a) was the most active member. This compound was not nearly as active as phenytoin against electrically induced convulsions, but was also active against pentylenetetrazole-induced seizures, suggesting a broader clinical potential. The closest analogue of phenytoin, viz., 5,5-diphenyl-2-iminohydantoin (1), failed to show any significant activity. Methylation on N-3 or the imino nitrogen of 1 also did not provide a compound with substantial activity. 2-Thiophenytoin was not active against electroshock seizures and showed only a weak activity against pentylenetetrazole. This study suggested that the structure-activity relationship of 2-iminohydantoins was quite different from that of 2-hydantoins.

  DOI：

  10.1021/jm00110a013

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2018118829A1

  公开（公告）日：2018-06-28

  The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

  本发明涉及Formula I化合物、包含这些化合物的药物组合物，以及它们在抑制HIV蛋白酶、抑制HIV复制、预防HIV感染、治疗HIV感染以及预防、治疗和延缓艾滋病发病或进展中的用途。
• A comparative investigation of supramolecular structures involving copper(ii) complexes of imidazolinylalkanimidamides
  作者：Michael M. Bishop、Leonard F. Lindoy、Daniel J. Miller、Peter Turner

  DOI：10.1039/b207031f

  日期：2002.11.12

  The syntheses of three new copper(II) complexes based on the bidentate ligand N-(4-oxo-5,5-diphenyl-4,5-dihydro-1H-imidazol-2-yl)ethanimidamide are reported. In the solid state these products assemble into elaborate supramolecular structures featuring hydrogen bonds within, and between, complexes as well as weak aryl–aryl and alkyl–aryl interactions between complexes; different coordination geometries and tautomeric forms are also observed. Dimethyl sulfoxide molecules show a variety of interactions within the structures, including coordination to the copper, hydrogen bonding, as well as weak alkyl–aryl interactions with the ligands.

  报告了基于二齿配体N-(4-氧代-5,5-二苯基-4,5-二氢-1H-咪唑-2-基)乙脒的三种新铜（II）配合物的合成。在固态下，这些产物组装成复杂的超分子结构，在配合物内部和之间存在氢键，在配合物之间存在弱的芳基-芳基和烷基-芳基相互作用；还观察到不同的配位几何结构和互变异构形式。二甲基亚砜分子在结构内表现出多种相互作用，包括与铜的配位、氢键以及与配体的弱烷基-芳基相互作用。
• 4-Oxo-2-hexahydropyrimidinylidene ureas
  申请人：McNeil Laboratories, Incorporated

  公开号：US04025517A1

  公开（公告）日：1977-05-24

  Compounds of the class of 4-oxo-2-imidazolidinylidene ureas and 4-oxo-2-hexahydropyrimidinylidene ureas, useful as anti-secretory agents and central nervous system (CNS) depressants.

  4-氧代-2-咪唑啉基脲和4-氧代-2-六氢嘧啶基脲这类化合物可用作抗分泌剂和中枢神经系统（CNS）抑制剂。
• Heterocyclic aspartyl protease inhibitors
  申请人：Zhu Zhaoning

  公开号：US20080200445A1

  公开（公告）日：2008-08-21

  Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O) 2 —, —C(═O)—, —O—, —C(R 6 )(R 7 )—, —N(R 5 )— or —C(═N(R 5 ))—; X is —O—, —N(R 5 )— or —C(R 6 )(R 7 )—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O) 2 —, —C(═O)— or —C(═NR 5 )—; U is a bond, —S(O)—, —S(O) 2 —, —C(O)—, —O—, —P(O)(OR 15 )—, —C(═NR 5 )—, —(C(R 6 )(R 7 )) b — or —N(R 5 )—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, U is not —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—; provided that when X is —N(R 5 )— and W is —S(O)—, —S(O) 2 —, —O—, or —N(R 5 )—, then U is not a bond; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula 1. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m 1 agonist or m 2 antagonist.

  本发明涉及公式I的化合物或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中W是键，—C(═S)—，—S(O)—，—S(O)2—，—C(═O)—，—O—，—C(R6)(R7)—，—N(R5)—或—C(═N(R5))—；X是—O—，—N(R5)—或—C(R6)(R7)—；但当X为—O—时，U不是—O—，—S(O)—，—S(O)2—，—C(═O)—或—C(═NR5)—；U是键，—S(O)—，—S(O)2—，—C(O)—，—O—，—P(O)(OR15)—，—C(═NR5)—，—(C(R6)(R7))b—或—N(R5)—；其中b为1或2；但当W为—S(O)—，—S(O)2—，—O—或—N(R5)—时，U不是—S(O)—，—S(O)2—，—O—或—N(R5)—；当X为—N(R5)—且W为—S(O)—，—S(O)2—，—O—或—N(R5)—时，U不是键；R1、R2、R3、R4、R5、R6和R7如规范中所定义；以及包括公式1的化合物的药物组合物。本发明还涉及抑制天冬氨酸蛋白酶的方法，特别是治疗心血管疾病、认知和神经退行性疾病的方法，以及抑制人类免疫缺陷病毒、贫血原虫、D蛋白酶和原虫酶的方法。本发明还涉及使用公式I的化合物与胆碱酯酶抑制剂或肌动蛋白m1受体激动剂或m2受体拮抗剂相结合治疗认知或神经退行性疾病的方法。
• Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
  申请人：Albert Jeffrey

  公开号：US20090176850A1

  公开（公告）日：2009-07-09

  This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及具有下面的结构式I的新化合物及其药学上可接受的盐、组合物和使用方法。这些新化合物可用于治疗或预防认知障碍、阿尔茨海默病、神经退行性疾病和痴呆症。